BOLD
Boundless Bio, Inc.
NASDAQ · USHealthcareBiotechnology
$2.44-1.61%
Price as of Jul 20, 2026
BOLD financials
Boundless Bio, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $1.3M | $1.1M | $0.00 | $0.00 |
| Gross profit | -$1.3M | -$1.1M | $0.00 | $0.00 |
| Operating expenses | $62.3M | $72.2M | $54.8M | $46.5M |
| Operating income | -$63.6M | -$73.3M | -$54.8M | -$46.5M |
| Net income | -$58.2M | -$65.4M | -$49.4M | -$45.9M |
| EBITDA | -$56.9M | -$64.3M | -$48.5M | -$45.0M |
| Basic EPS | $-2.60 | $-3.85 | $-2.22 | $-2.06 |
| Diluted EPS | $-2.60 | $-3.85 | $-2.22 | $-2.06 |
| Balance sheet | ||||
| Cash & equivalents | $17.9M | $26.6M | $23.7M | $11.0M |
| Total assets | $157.1M | $206.4M | $129.9M | $76.8M |
| Total liabilities | $58.4M | $55.8M | $257.0M | $158.5M |
| Stockholders’ equity | $98.7M | $150.6M | -$127.1M | -$81.7M |
| Total debt | $49.0M | $47.6M | $2.2M | $5.2M |
| Net debt | $31.2M | $21.0M | -$21.5M | -$5.8M |
| Cash flow | ||||
| Operating cash flow | -$46.7M | -$60.8M | -$46.9M | -$39.6M |
| Capital expenditure | -$546.0K | -$2.5M | -$633.0K | -$1.1M |
| Free cash flow | -$47.2M | -$63.4M | -$47.5M | -$40.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |